Clinical Trial Update: Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Lparomlimab and Tuvonralimab in combination with TACE and lenvatinib as second-line therapy for unresectable intermediate-to-advanced…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Lparomlimab (Lparomlimab)
• Tuvonralimab (tuvonralimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: HCC | Phase 2 | Status: RECRUITING